

Special Issue

Advanced Ovarian Cancer

Message from the Guest Editor

In the past decade, there has been significant progress in the evaluation and treatment of advanced ovarian cancer in addition to a combination of debulking surgery and systemic chemotherapy, such as homologous recombination deficiency evaluation, hyperthermic intraperitoneal chemotherapy, anti-vascular endothelial growth factor therapy, poly ADP-ribose polymerase inhibitor, and even immune check point inhibitor.

However, the prognosis of a significant portion of patients with advanced ovarian cancer remains poor. Thus, we need to study hard to determine the optimal evaluation and treatment strategies. We welcome submissions in advanced or recurrent ovarian cancer that cover any relevant topic in the areas of risk assessment and stratification, medical and surgical management strategies.

Guest Editor

Prof. Sheng-Mou Hsiao

1. Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital, Banqiao, New Taipei 220216, Taiwan
2. Graduate School of Biotechnology and Bioengineering, Yuan Ze University, Taoyuan 320315, Taiwan
3. Department of Obstetrics and Gynecology, National Taiwan University College of Medicine and Hospital, Taipei 100226, Taiwan

Deadline for manuscript submissions

closed (30 November 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/159967

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)